Alexion Pharma v. Amgen Canada
| Jurisdiction | Federal Jurisdiction (Canada) |
| Court | Federal Court (Canada) |
| Citation | 2025 FC 754 |
| Date | 12 May 2025 |
Get this document and AI-powered insights with a free trial of vLex and Vincent AI
Get Started for FreeUnlock full access with a free 7-day trial
Transform your legal research with vLex
-
Complete access to the largest collection of common law case law on one platform
-
Generate AI case summaries that instantly highlight key legal issues
-
Advanced search capabilities with precise filtering and sorting options
-
Comprehensive legal content with documents across 100+ jurisdictions
-
Trusted by 2 million professionals including top global firms
-
Access AI-Powered Research with Vincent AI: Natural language queries with verified citations
Unlock full access with a free 7-day trial
Transform your legal research with vLex
-
Complete access to the largest collection of common law case law on one platform
-
Generate AI case summaries that instantly highlight key legal issues
-
Advanced search capabilities with precise filtering and sorting options
-
Comprehensive legal content with documents across 100+ jurisdictions
-
Trusted by 2 million professionals including top global firms
-
Access AI-Powered Research with Vincent AI: Natural language queries with verified citations
Unlock full access with a free 7-day trial
Transform your legal research with vLex
-
Complete access to the largest collection of common law case law on one platform
-
Generate AI case summaries that instantly highlight key legal issues
-
Advanced search capabilities with precise filtering and sorting options
-
Comprehensive legal content with documents across 100+ jurisdictions
-
Trusted by 2 million professionals including top global firms
-
Access AI-Powered Research with Vincent AI: Natural language queries with verified citations
Unlock full access with a free 7-day trial
Transform your legal research with vLex
-
Complete access to the largest collection of common law case law on one platform
-
Generate AI case summaries that instantly highlight key legal issues
-
Advanced search capabilities with precise filtering and sorting options
-
Comprehensive legal content with documents across 100+ jurisdictions
-
Trusted by 2 million professionals including top global firms
-
Access AI-Powered Research with Vincent AI: Natural language queries with verified citations
Unlock full access with a free 7-day trial
Transform your legal research with vLex
-
Complete access to the largest collection of common law case law on one platform
-
Generate AI case summaries that instantly highlight key legal issues
-
Advanced search capabilities with precise filtering and sorting options
-
Comprehensive legal content with documents across 100+ jurisdictions
-
Trusted by 2 million professionals including top global firms
-
Access AI-Powered Research with Vincent AI: Natural language queries with verified citations
Start Your 7-day Trial
8 practice notes
-
Adeia Guides Inc. v. Videotron Ltd., 2025 FC 1725
...the disclosure condition is satisfied. [34] As recently stated by Justice Furlanetto in Alexion Pharmaceuticals, Inc v Amgen Canada Inc, 2025 FC 754: [62] As noted in Takeda at paragraph 153, disclosure may be made without any recognition of what is present or what is happening: see Abbott ......
-
Canadian Patent Law 2025: A Year In Review
...decisions in 2025 considered the use of multiple documents in assessing anticipation. InAlexion Pharmaceuticals, Inc v Amgen Canada Inc, 2025 FC 754, the Federal Court accepted that a prior anticipatory disclosure could comprise teachings from more than a single document in instances where ......
-
Life Sciences In Canada: Year In Review 2025
...See our overview of the arguments raised before the SCC here, and our in-depth review of the FCA decision here. 2. Alexion v Amgen, 2025 FC 754: Alexion's eculizumab patent withstands anticipation and obviousness In 2025, there was only one decision on the merits for a pharmaceutical patent......
-
Canadian Patent Law In Review 2025: Notable Decisions And Updates
...Against Biosimilar and Considers Anticipation by Incorporation by Reference: Alexion Pharmaceuticals, Inc. v. Amgen Canada Inc., 2025 FC 754 The New Due Care Roadmap: How to Avoid Deemed Expiry or Abandonment of Your Patent and Design Rights Federal Court Finds Liability for Common Design I......
Get Started for Free
7 firm's commentaries
-
Canadian Patent Law 2025: A Year In Review
...decisions in 2025 considered the use of multiple documents in assessing anticipation. InAlexion Pharmaceuticals, Inc v Amgen Canada Inc, 2025 FC 754, the Federal Court accepted that a prior anticipatory disclosure could comprise teachings from more than a single document in instances where ......
-
Life Sciences In Canada: Year In Review 2025
...See our overview of the arguments raised before the SCC here, and our in-depth review of the FCA decision here. 2. Alexion v Amgen, 2025 FC 754: Alexion's eculizumab patent withstands anticipation and obviousness In 2025, there was only one decision on the merits for a pharmaceutical patent......
-
Canadian Patent Law In Review 2025: Notable Decisions And Updates
...Against Biosimilar and Considers Anticipation by Incorporation by Reference: Alexion Pharmaceuticals, Inc. v. Amgen Canada Inc., 2025 FC 754 The New Due Care Roadmap: How to Avoid Deemed Expiry or Abandonment of Your Patent and Design Rights Federal Court Finds Liability for Common Design I......
-
Canadian Patent Law: 2025 In Review
...by reference The only trial decision under Canada's Patented Medicines (Notice of Compliance) Regulations of 2025, Alexion v Amgen (2025 FC 754) concerned a challenge by Amgen to CA2,645,810 which covers Alexion's SOLIRIS (eculizumab) product. Infringement was conceded, with anticipation an......
Get Started for Free